[HTML][HTML] 作者: CN-INFO 责任编辑: 文传商讯2019-03-11 10: 11: 00 来源: 文传商讯关键字: null
JBW OSAKA - cbinews.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
[HTML][HTML] 每日热点网-国际综合资讯平台admin 2019-03-12 16: 51
JBW OSAKA - mrrdw.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
[HTML][HTML] Vedolizumab (Entyvio (R)) Ac
JBW OSAKA - jiangximinsheng.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
[HTML][HTML] 每日热点网-国际综合资讯平台admin 2019-09-26 17: 48
JBW OSAKA - mrrdw.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced further results from the VARSITY study, which demonstrated the superiority of …
announced further results from the VARSITY study, which demonstrated the superiority of …
[HTML][HTML] Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever Head-to-Head Biologic Clinical Study in …
JBW OSAKA - 2019 - finet.hk
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
[HTML][HTML] First Head-to-Head Bio
JBW OSAKA - jiangximinsheng.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced further results from the VARSITY study, which demonstrated the superiority of …
announced further results from the VARSITY study, which demonstrated the superiority of …
[HTML][HTML] First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab
JBW OSAKA - 2019 - finet.hk
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced further results from the VARSITY study, which demonstrated the superiority of …
announced further results from the VARSITY study, which demonstrated the superiority of …
[HTML][HTML] Highlights in the Management of Ulcerative Colitis and Crohn's Disease From the 2019 Digestive Disease Week Meeting
GR Lichtenstein - Gastroenterology & …, 2019 - gastroenterologyandhepatology.net
The VARSITY trial (A Double-Blind, Double-Dummy, Randomised, Controlled Trial of
Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis) was the first …
Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis) was the first …
Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
S Motoya, K Watanabe, H Ogata, T Kanai, T Matsui… - PloS one, 2019 - journals.plos.org
Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized,
double-blind, placebo-controlled st Page 1 CORRECTION Correction: Vedolizumab in …
double-blind, placebo-controlled st Page 1 CORRECTION Correction: Vedolizumab in …
S288 Clinical Effectiveness of Vedolizumab in Chinese Ulcerative Colitis Patients: Results From the VALUE Study
B Chen, L Xie, Y Liu, M Chen - … journal of the American College of …, 2023 - journals.lww.com
Methods: VALUE study is a prospective, multicenter, single-armed observational study to
evaluate the safety and effectiveness of VDZ in the Chinese population, with a study sample …
evaluate the safety and effectiveness of VDZ in the Chinese population, with a study sample …